221 related articles for article (PubMed ID: 9816257)
21. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial of combined 131I anti-CEA monoclonal antibody and hyperthermia in patients with advanced colorectal adenocarcinoma.
Mittal BB; Zimmer MA; Sathiaseelan V; Benson AB; Mittal RR; Dutta S; Rosen ST; Spies SM; Mettler JM; Groch MW
Cancer; 1996 Nov; 78(9):1861-70. PubMed ID: 8909304
[TBL] [Abstract][Full Text] [Related]
24. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
25. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen.
Sharkey RM; Pykett MJ; Siegel JA; Alger EA; Primus FJ; Goldenberg DM
Cancer Res; 1987 Nov; 47(21):5672-7. PubMed ID: 3664474
[TBL] [Abstract][Full Text] [Related]
26. Comparison of multiple bolus and continuous injections of 131I-labeled CC49 for therapy in a colon cancer xenograft model.
Buchsbaum DJ; Khazaeli MB; Mayo MS; Roberson PL
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3153s-3159s. PubMed ID: 10541357
[TBL] [Abstract][Full Text] [Related]
27. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
Juweid ME; Stadtmauer E; Hajjar G; Sharkey RM; Suleiman S; Luger S; Swayne LC; Alavi A; Goldenberg DM
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3292s-3303s. PubMed ID: 10541378
[TBL] [Abstract][Full Text] [Related]
29. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial.
Behr TM; Memtsoudis S; Vougioukas V; Liersch T; Gratz S; Schmidt F; Lorf T; Post S; Wörmann B; Hiddemann W; Ringe B; Becker W
Anticancer Res; 1999; 19(4A):2427-32. PubMed ID: 10470170
[TBL] [Abstract][Full Text] [Related]
30. Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.
Meredith RF; Khazaeli MB; Macey DJ; Grizzle WE; Mayo M; Schlom J; Russell CD; LoBuglio AF
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3254s-3258s. PubMed ID: 10541372
[TBL] [Abstract][Full Text] [Related]
31. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Reardon DA; Zalutsky MR; Akabani G; Coleman RE; Friedman AH; Herndon JE; McLendon RE; Pegram CN; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Guruangan S; Boulton S; Raynor RH; Dowell JM; Wong TZ; Zhao XG; Friedman HS; Bigner DD
Neuro Oncol; 2008 Apr; 10(2):182-9. PubMed ID: 18287339
[TBL] [Abstract][Full Text] [Related]
32. A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
Meyer T; Gaya AM; Dancey G; Stratford MR; Othman S; Sharma SK; Wellsted D; Taylor NJ; Stirling JJ; Poupard L; Folkes LK; Chan PS; Pedley RB; Chester KA; Owen K; Violet JA; Malaroda A; Green AJ; Buscombe J; Padhani AR; Rustin GJ; Begent RH
Clin Cancer Res; 2009 Jul; 15(13):4484-92. PubMed ID: 19549771
[TBL] [Abstract][Full Text] [Related]
33. Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions.
Richman CM; DeNardo SJ; O'Grady LF; DeNardo GL
Cancer Res; 1995 Dec; 55(23 Suppl):5916s-5920s. PubMed ID: 7493370
[TBL] [Abstract][Full Text] [Related]
34. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
Zalutsky MR; McLendon RE; Garg PK; Archer GE; Schuster JM; Bigner DD
Cancer Res; 1994 Sep; 54(17):4719-25. PubMed ID: 8062270
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma.
Chong G; Lee FT; Hopkins W; Tebbutt N; Cebon JS; Mountain AJ; Chappell B; Papenfuss A; Schleyer P; U P; Murphy R; Wirth V; Smyth FE; Potasz N; Poon A; Davis ID; Saunder T; O'keefe GJ; Burgess AW; Hoffman EW; Old LJ; Scott AM
Clin Cancer Res; 2005 Jul; 11(13):4818-26. PubMed ID: 16000579
[TBL] [Abstract][Full Text] [Related]
36. Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer.
Welt S; Divgi CR; Kemeny N; Finn RD; Scott AM; Graham M; Germain JS; Richards EC; Larson SM; Oettgen HF
J Clin Oncol; 1994 Aug; 12(8):1561-71. PubMed ID: 8040668
[TBL] [Abstract][Full Text] [Related]
37. Radioimmunotherapy of small cell lung carcinoma with the two-step method using a bispecific anti-carcinoembryonic antigen/anti-diethylenetriaminepentaacetic acid (DTPA) antibody and iodine-131 Di-DTPA hapten: results of a phase I/II trial.
Vuillez JP; Kraeber-Bodéré F; Moro D; Bardiès M; Douillard JY; Gautherot E; Rouvier E; Barbet J; Garban F; Moreau P; Chatal JF
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3259s-3267s. PubMed ID: 10541373
[TBL] [Abstract][Full Text] [Related]
38. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
39. Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.
Lindén O; Tennvall J; Cavallin-Ståhl E; Darte L; Garkavij M; Lindner KJ; Ljungberg M; Ohlsson T; Sjögreen K; Wingårdh K; Strand SE
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3287s-3291s. PubMed ID: 10541377
[TBL] [Abstract][Full Text] [Related]
40. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
Breitz HB; Weiden PL; Vanderheyden JL; Appelbaum JW; Bjorn MJ; Fer MF; Wolf SB; Ratliff BA; Seiler CA; Foisie DC
J Nucl Med; 1992 Jun; 33(6):1099-109. PubMed ID: 1597723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
